Industry Representative to the US FDA Oncologic Drugs Advisory Committee (ODAC) @ (October 2019 - April 2024)
Oncology Global Regulatory Strategy Portfolio Lead @ (January 2011 - March 2023)
Vice President: Medicine Development @ Onyx Pharmaceuticals (acquired Proteolix)(acquired by Amgen) (November 2009 - January 2011)
Vice President: Regulatory Affairs and Quality Assurance @ Proteolix (acquired by Onyx Pharmaceutricals) (August 2008 - November 2009)
Board Member @ Kosan Bioscience Europe LTD (April 2006 - October 2008)
Vice President: Drug Development, Pharmacovigilance and Regulatory Affairs @ (January 2006 - August 2008)
Group Director: Global Regulatory Strategy and US FDA Liason @ (January 1997 - January 2006)
Section Head, Toxicology, Human Safety and Regulatory Affairs @ (January 1985 - January 1997)
Albert Kraus Education
University of Michigan
PhD (Biochemical Toxicology/ Cellular Chemistry)
1981-1985
Hamilton College
AB (Biology, Economics)
1977-1981
Albert Kraus Summary
Albert Kraus, based in Guilford, CT, US, is currently a Entrepreneur in Residence at Yale University. Albert Kraus brings experience from previous roles at GDS Partners LLC, NDA Group AB, FDA and Pfizer. Albert Kraus holds a 1981 - 1985 PhD in Biochemical Toxicology/ Cellular Chemistry @ University of Michigan. Albert Kraus has 1 emails on RocketReach.
Looking for a different Albert Kraus?
Find contact details for 700 million professionals.